Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Other Non-Current Assets (2021 - 2025)

Lyra Therapeutics has reported Other Non-Current Assets over the past 5 years, most recently at $2.0 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $2.0 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $2.0 million (changed 0.0% YoY), and the annual figure for FY2025 was $2.0 million, changed 0.0%.
  • Other Non-Current Assets for Q4 2025 was $2.0 million at Lyra Therapeutics, roughly flat from $2.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for LYRA hit a ceiling of $7.5 million in Q3 2023 and a floor of $243000.0 in Q2 2021.
  • Median Other Non-Current Assets over the past 5 years was $1.4 million (2023), compared with a mean of $1.7 million.
  • Biggest five-year swings in Other Non-Current Assets: surged 585.31% in 2023 and later tumbled 73.31% in 2024.
  • Lyra Therapeutics' Other Non-Current Assets stood at $700000.0 in 2021, then soared by 368.71% to $3.3 million in 2022, then crashed by 57.57% to $1.4 million in 2023, then surged by 43.18% to $2.0 million in 2024, then changed by 0.0% to $2.0 million in 2025.
  • The last three reported values for Other Non-Current Assets were $2.0 million (Q4 2025), $2.0 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.